    |
| Product（Packaging）产品和包转 | 中文名 | CAS # | In Stock |
| Abiraterone Acetate (200 mg) | 乙酸阿比特龙酯 | 154229-18-2 | Yes |
| Abiraterone System Suitability Mixture (20 mg) | 阿比特龙系统适用性混合物 | Yes | |
| Aleuritic Acid (50 mg) | 紫胶桐酸 | 533-87-9 | Yes |
| Amantadine Related Compound B (25 mg) (N-(Adamantan-1-yl)acetamide) | 乙酰金刚烷胺 | 880-52-4 | Yes |
| Budesonide Related Compound E (25 mg) (16alpha,17-[butylidenebis(oxy)]-11Beta,21-dihydroxypregna-1,4,14-triene-3,20-dione) | 131918-64-4 | Yes | |
| Calycosin (50 mg) (7-Hydroxy-3-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one) | 毛蕊异黄酮 | 20575-57-9 | Yes |
| Candesartan Cilexetil Related Compound A (10 mg) (Ethyl 1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-2-ethoxybenzimidazole-7-carboxylate) | 坎地沙坦酯杂质A | Yes | |
| Candesartan Cilexetil Related Compound B (10 mg) (1-(Cyclohexyloxycarbonyloxy)ethyl 1-{[2'-(1H- tetrazol-5-yl)biphenyl-4-yl]methyl}-2-oxo-2,3-dihydrobenzimidazole-7-carboxylate) | 坎地沙坦酯杂质B | Yes | |
| Candesartan Cilexetil Related Compound D (10 mg) (1-{[(Cyclohexyloxy)carbonyl]oxy}ethyl 3-({2'-(2-ethyl-2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl}methyl)-2-oxo-2,3-dihydro-1H-benzimidazole-4-carboxylate) | 坎地沙坦酯杂质D | Yes | |
| Candesartan Cilexetil Related Compound F (10 mg) (1-(Cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-{[2'-(2-ethyl-2H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate) | 坎地沙坦酯杂质F | Yes | |
| Capric Alcohol (5 x 30 mg) | Yes | ||
| Chlorophyll A (15 mg) | 叶绿素A | 479-61-8 | Yes |
| Daunorubicinone (25 mg) ((8S,10S)-8-Acetyl-6,8,10,11-tetrahydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione) | 柔红酮 | 21794-55-8 | Yes |
| Desfluoro Aprepitant (15 mg) (5-{[(2R,3S)-2-{(R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-3-phenylmorpholino]methyl}-2H-1,2,4-triazol-3(4H)-one) | 170729-76-7 | Yes | |
| Dihydrodaunorubicin Hydrochloride (20 mg) ((8S,10S)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-6,8,11-trihydroxy-8-(1-hydroxyethyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride) | Yes | ||
| Diphenhydramine N-Oxide (25 mg) (2-(benzhydryloxy)-N,N-dimethylethan-1-amine oxide hydrochloride) | 13168-00-8 | Yes | |
| Doxorubicinone (25 mg) ((8S,10S)-6,8,10,11-Tetrahydroxy-8-(hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione) | 24385-10-2 | Yes | |
| Ezetimibe (250 mg) | 163222-33-1 | Yes | |
| Ezetimibe System Suitability Mixture (20 mg) | Yes | ||
| Fluticasone Propionate Related Compound D (15 mg) (S-methyl 6alpha, 9alpha-difluoro-11beta-hydroxy-16alpha-methyl-3-oxo-17alpha-propionyloxyandrosta-1,4-diene-17beta-carbothioate) | Yes |
